Improve Digital Enhances Video Ad Targeting with Digital Element’s Location-Based Technology
14.8.2017 10:00:00 EEST | Business Wire | Press release
Digital Element, the leading provider of IP geolocation technology, today announced Improve Digital, the all-in-one advertising platform for publishers, content providers, and broadcasters, has adopted its NetAcuity Edge hyperlocal targeting solution to ensure its customers can serve the right ads, to the right audience, in the right location.
Digital Element’s technology has been integrated into 360 Polaris, Improve Digital’s full stack monetisation technology platform for video, web, and mobile content providers. This programmatic advertising solution integrates both a premium ad server and a supply side platform to help content providers maximise revenue in a fully transparent way. Improve Digital has more than 250 media partners, and works with major brands including Hearst, eBay, IDG, and more.
Improve Digital selected Digital Element to increase the granularity and accuracy of its geographic targeting data and meet the growing demands of its premium clients and their advertisers. The 360 Polaris technology works across all formats and devices – incorporating video, native advertising, rich media, and display ads – so it is vital Improve Digital can identify the consumer’s location to serve accurately targeted and correctly optimised ads. By incorporating the NetAcuity Edge™ technology, Improve Digital allows its clients to better understand their customers’ locations and provides unrivalled targeting precision for video advertising across multiple devices. Also the deployment of additional Digital Element databases connection type, ISP and mobile carrier provides supplementary targeting capabilities.
“Our business is built on providing accurate insights into high-value ad inventory and audiences, being a trusted and transparent partner to our clients and serving the best interests of publishers, content providers, and broadcasters,” commented Garry Turkington, Chief Technology Officer of Improve Digital. “The quality of service we provide depends on a reliable, transparent, and trusted source of data, and Digital Element's geolocation technology broadens and complements our product offering both globally and locally, further elevating our position in the marketplace.”
Digital Element’s NetAcuity Edge™ combines traditional infrastructure analysis with insight gleaned from a network of global commercial partners to better map the internet. The result is the most granular and accurate hyperlocal geotargeting solution that maintains user anonymity and complies with the highest standards of end-user privacy.
Charlie Johnson, Digital Element’s Vice President, UK & Ireland, commented: “Improve Digital is a leading player in the video advertising industry, and their ability to provide a premium service for content providers is reliant on high quality data to form accurate targeting profiles. This will be made possible by the integration of our exceptionally granular hyperlocal data into the 360 Polaris platform, and we look forward to helping them achieve the standards expected by their impressive client base.”
Improve Digital joins Digital Element’s portfolio of high-profile clients which includes: Disney Interactive, Sony Pictures, CNN, BBC, ESPN, Channel 5, Hulu, CBS Interactive, YouView, Turn, Videology and Teads.tv.
<ENDS>
About Digital Element
Since 1999, Digital Element has been providing global geolocation solutions that bring anytime, anywhere relevance and context to online initiatives ― from desktops to mobile devices. The company’s patented technology has been certified and accredited to deliver real-time access to accurate and reliable location intelligence without invading Internet users’ privacy. For more than a decade, many of the world’s largest websites, brands, ad networks, social media platforms and mobile publishers have trusted Digital Element’s technology to target advertising, localise content, enhance analytics, and manage content rights as well as detect and prevent fraud. Visit http://www.digitalelement.com for more information on how to bring the power of location to the online world. Headquartered in Atlanta and London, Digital Element is a division of Digital Envoy Inc.
About Improve Digital
Improve Digital is the All-in-One Advertising Platform for Publishers, Content Providers and Broadcasters.
Improve Digital’s mission is to build smart, efficient, and responsible digital businesses for its enterprise customers. It creates the technology that makes advertising marketplaces possible. Content providers, digital publishers and broadcasters use that technology to monetise their video, mobile and web advertising inventory.
The company works with over 250 of the world’s top media owners and, through them, supports the efforts of 112,000 advertisers each month. Improve Digital is a Swisscom company with offices located in London, Amsterdam, Munich, Antwerp, Milan, Barcelona and Paris.
For more information, please visit http://www.improvedigital.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170814005061/en/
Contact information
GingerMay PR for Digital Element
Naomi Whittome
Naomi.whittome@gingermaypr.com
+44
(0) 203 642 1124
or
Improve Digital
Henriëtte Gathier
h.gathier@improvedigital.com
+31
(0) 623824823
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
